Cabrera, Silverio A.
HRN: 21-84-17 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/25/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
08/25/2022
09/01/2022
IV
500mg
Q8H
PMBO
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes